Onkologie. 2019:13(4):162-166 | DOI: 10.36290/xon.2019.031

Factors affecting breakthrough pain

Lukáš Pochop
Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

The term “breakthrough pain” was coined in 1990; however, the concept as well as therapeutic approaches have significantly evolved since that time. It was not only transmucosal fentanyl formulations that have broadened the armamentarium of treatment options and contributed to effective breakthrough pain management. Moreover, the abundance of analgesic interventions have also increased the number of combinations and strategies used for pain relief. Therapeutic decisions should be tailored for each patient based on a comprehensive assessment of individual aspects of pain and patient preferences. Understanding of this issue increases the expertise of health professionals and improves treatment outcomes in patients with breakthrough pain.

Keywords: breakthrough cancer pain, transmucosal fentanyl, opioids, psycho-oncology

Published: September 15, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pochop L. Factors affecting breakthrough pain. Onkologie. 2019;13(4):162-166. doi: 10.36290/xon.2019.031.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990; 41: 273-281. Go to original source... Go to PubMed...
    2. L?hre ET, Klepstad P, Bennett MI, et al. European Association for Pa - lliative Care Research Network. From "breakthrough" to "episodic" cancer pain? A European Association for Palliative Care Research Network expert Delphi survey toward a common terminology and classification of transient cancer pain exacerbations. J Pain Symptom Manage 2016; 51: 1013-1019. Go to original source... Go to PubMed...
    3. Haugen DF, Hjermstad MJ, Hagen N. Assessment and classification of cancer breakthrough pain: a systematic literature review. Pain. 2010; 149(3): 476-482. Go to original source... Go to PubMed...
    4. Sláma O. Průlomová nádorová bolest v klinické praxi. Bolest. 2017; 20(4): 169-172.
    5. Davies A, Buchanan A, Zeppetella G, et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manage 2013; 46: 619-628. Go to original source... Go to PubMed...
    6. Garassino MC, et al. Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients. PLoS One 2013. Go to original source...
    7. O'Hagan P, Mercadante S. Breakthrough cancer pain: The importance of the right treatment at the right time. Eur J Pain. 2018; 22(7): 1362-1374. Go to original source... Go to PubMed...
    8. Dostupné z: https://www.linkos.cz/files/modra-kniha/18/698.pdf (5/2019).
    9. Vieira CMP, Fragoso RM, et al. Pain polymorphisms and opioids: An evidence based review. Mol Med Rep. 2019; 19(3): 1423-1434.
    10. Mogil JS, Wilson SG, Et al. The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc Natl Acad Sci U S A. 2003; 100(8): 4867-4872. Go to original source... Go to PubMed...
    11. Bandieri E, Romero M, Ripamonti CI, et. al, Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain. J Clin Oncol. 2016; 34(5): 436-442. Go to original source... Go to PubMed...
    12. Mercadante S, Prestia G, Casuccio A. The use of sublingual fentanyl for breakthrough pain by using doses proportional to opioid basal regimen. Curr Med Res Opin 2013; 29: 1527-1532. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.